



Smith & Hopon, P.A.

Intellectual Property Law Patents Trademarks Copyrights

#5 1635

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

December 13, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

Applicants: Loree Heller et al.

Serial No.: 10/064,512

Filing Date: 07/23/2002

For: Method of Enhancing Therapeutic Effect of Nucleic Acids

Our Reference No.: 1372.48

Examiner: Brian A. Whiteman

Art Unit: 1635

Dear Sir:

Enclosed please find the following:

1. Information Disclosure Statement By Applicants- 1 page;
2. Copies of the of nine (9) Non-Patent Literature Documents; and
3. Self-addressed, postage prepaid post card to serve as a receipt for items 1-2.

Very respectfully,

SMITH & HOPEN

By: Anton J. Hopon

anton.hopen@baypatents.com

AJH/nc
enclosure

**CERTIFICATE OF MAILING
(37 C.F.R. 1.8)**

I HEREBY CERTIFY that this correspondence is being mailed with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on December 13, 2002.

Date: December 13, 2002


Nicole Carnell

Attorney-Client Privileged Communication

15950 Bay Vista Drive, Suite 220 Clearwater, Florida 33760, USA
Phone: (727) 507-8558 Fax: (727) 507-8668
Internet: www.baypatents.com

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/064,512
Filing Date 07/23/2002
First Named Inventor Loree Heller
Group Art Unit 1635
Examiner Name Brian A. Whiteman
Attorney Docket Number 1372.48

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	1	Bird, Adrian P., CpG-rich islands and the function of DNA methylation	
✓	2	Krieg et al., CpG motifs in bacterial DNA trigger direct B-cell activation	
✓	3	Krieg et al., Mechanism of Action of CpG DNA	
✓	4	Tokunaga et al., Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.	
✓	5	Yamamoto et al., In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG	
✓	6	Weiner, et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization	
✓	7	Liu et al., Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor	
✓	8	Dow et al., Lipid-DNA Complexes Induce Potent Activation of Innate Immune Responses and Antitumor Activity When Administered Intravenously	
✓	9	McMahon et al., Inflammatory responses following direct injection of plasmid DNA into skeletal muscle.	

Examiner Signature	Date Considered
--------------------	-----------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.